(Alliance News) - AstraZeneca PLC said on Monday that the US Food & Drug Aadministration has approved Lynparza as a treatment of metastatic pancreatic cancer.
AstraZeneca co-develops and co-commercialises Lynparza, together with Merck & Co Inc.
The US regulator approved the treatment following a recommendation from its Oncologic Drugs Advisory Committee, which was based on results from the phase III POLO trial. it showed Lynparza nearly doubled the time patients with pancreatic cancer lived without disease progression or death to a median of 7.4 months compared to 3.8 months on the placebo.
Dave Fredrickson, executive vice president of the Oncology unit of AstraZeneca: "Patients with advanced pancreatic cancer historically have faced poor outcomes due to the aggressive nature of the disease and limited treatment advances over the last few decades. Lynparza is now the only approved targeted medicine in biomarker-selected patients with advanced pancreatic cancer."
By Ife Taiwo; ifetaiwo@alliancenews.com
Copyright 2019 Alliance News Limited. All Rights Reserved.
Astrazeneca (AZN)